Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy
Sangraula, H.; Sharma, K.K.; Dwivedi, S.
National Medical Journal of India 14(6): 347-348
2001
ISSN/ISBN: 0970-258X PMID: 11804366 Document Number: 535572
Document emailed within 1 workday
Related Documents
Cabot de Vega, E.; Fontecha Gómez, B.J.; Solé Arnau, R.; Pedrol Clotet, E. 1999: Peripheral lipodystrophy associated with protease inhibitor therapy Revista Clinica Espanola 199(8): 546-547Ritt, M.J.; Hillebrand-Haverkort, M.E.; ten Veen, J.H. 2001: Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy Acta Chirurgiae Plasticae 43(2): 54-56
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Bard, J-Marie.; Lassalle, Régis.; Capeau, J.; Bach-Ngohou, K.; Nazih-Sanderson, Fçoise.; Rémy, Gérard.; Reynes, J.; Ecobichon, J-Luc.; Savès, M.; Raffi, Fçois. 2006: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy Antiviral Therapy 11(3): 361-370
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Jazet, I.M.; Jonker, J.T.; Wijngaarden, M.A.; Lamb, H.; Smelt, A.H.M. 2013: Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement Nederlands Tijdschrift Voor Geneeskunde 157(4): A5482
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Walker, A.R.; Walker, B.F.; Manetsi, B.; Molefe, O.; Walker, A.J.; Vorster, H.H. 1991: Obesity in indigent elderly rural African women: effects on hypertension, hyperlipidaemia and hyperglycaemia International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift für Vitamin- und Ernahrungsforschung. Journal International de Vitaminologie et de Nutrition 61(3): 244-250
Parakh, A.; Dubey, A.P.; Kumar, A.; Maheshwari, A. 2009: Lipodystrophy and metabolic complications of highly active antiretroviral therapy Indian Journal of Pediatrics 76(10): 1017-1021
Hoffmann, F.; Funk, M.; Linde, R.; Notheis, G.; Petropoulou, T.; Eberle, J.; Gürtler, L.; Belohradsky, B.H.; Wintergerst, U. 2002: Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection European Journal of Medical Research 7(7): 330-334
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Lapphra, K.; Vanprapar, N.; Phongsamart, W.; Chearskul, P.; Chokephaibulkit, K. 2005: Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART) Journal of the Medical Association of Thailand 88(7): 956-966
Chuapai, Y.; Kiertiburanakul, S.; Malathum, K.; Sungkanuparph, S. 2007: Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy Journal of the Medical Association of Thailand 90(3): 452-458
Ni, L.; Wang, R-Bing.; Guo, H-Jun.; Tan, X-Hua.; Sun, L-Jun.; Zheng, Y-Huang.; Duan, C-Yu.; Hu, D-Qing.; Wang, W-Jing.; Wang, Y-Guang.; Zhao, H-Xin. 2013: Multi-centered, randomized controlled clinical study on Chinese medicine formula particles for hyperlipidaemia associated with highly active antiretroviral therapy Zhongguo Zhong Yao Za Zhi 38(15): 2443-2447
Besson, C.; Jubault, V.; Viard, J.P.; Pialoux, G. 1998: Ketoacidosis associated with protease inhibitor therapy Aids 12(11): 1399-1400
Mercier, S.; Gueye, N.F.N.; Cournil, A.; Fontbonne, A.; Copin, N.; Ndiaye, I.; Dupuy, A.-M.; Cames, C.éc.; Sow, P.S.; Ndoye, I.; Delaporte, E.; Simondon, K.B. 2009: Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study Journal of Acquired Immune Deficiency Syndromes 51(2): 224-230
Piloya, T.; Bakeera-Kitaka, S.; Kekitiinwa, A.; Kamya, M.R. 2012: Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study Journal of the International Aids Society 15(2): 17427
Werner, M.L.F.; Pone, M.V.d.S.; Fonseca, V.ân.M.; Chaves, C.él.R.M.d.M. 2010: Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy Jornal de Pediatria 86(1): 27-32
Werner, M.L.F.; Pone, M.V.d.S.; Fonseca, V.ân.M.; Chaves, C.él.R.M.d.M. 2010: Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy Jornal de Pediatria 86(1): 27-32